Velma Seabolt C.R.N.P.

Education

1995 OB/GYN Ultrasound Course, Boise State University
1994 Obstetrical and Transvaginal Ultrasound-Level II, University of California, Irvine
1993 Fundamentals of Obstetrical Ultrasound, Memorial/UCI

• Master of Science in Nursing, California State University

1988 Certification, Women’s Health Care, Nurse Practitioner Program, Harbor UCLA Medical Center
1987 Certification, Lactation Consultant Program, Evergreen Medical Center

• Bachelor of Science, Nursing, Montana State University, Bozeman, MT

Licensure

RN License, State of Idaho #N-17961
Nurse Practitioner License, State of Idaho #NP-199A

Professional Organizations

1988-Present Organization of Obstetric, Gynecologic and Neonatal Nurses (NAACOG)

1990-Present Idaho Nurse Practitioner Coalition

Work Experience

1994 - present OB/GYN Nurse Practitioner, Office of Brenda Williams
1992 OB/GYN Nurse Practitioner, Les Bois OB/GYN, P.A. Boise, ID
1991 OB/GYN Nurse Practitioner, 366th Medical Group TAC Hospital, Mountain Home AFB, ID
1990 OB/GYN Nurse Practitioner, Central District Health Department, Boise, ID
1990 Nurse Educator, Idaho Perinatal Project, Boise, ID
1988-1990 OB/GYN Nurse Practitioner, Planned Parenthood of Idaho, Boise, ID
1986-1988 Staff Nurse, Labor & Delivery, St. Luke’s Regional Medical Center, Boise, ID
1985-1986 Staff Nurse, Labor & Delivery, Hackley Hospital, Muskegon, MI
1982-1985 Staff Nurse, Labor & Delivery, House Supervisor, 366th Medical Group TAC Hospital, Mountain Home AFB,

Velma Seabolt, C.R.N.P.
Research Associates
333 North First Street, Suite 250
Boise, ID 83702

Office Phone:             (208) 384-5977
Office Fax:                 (208) 345-7270

Additional Offices:     Women’s Health Associates
                                333 North First Street, Suite 240
                                Boise, ID 83702
                                Office Phone: (208) 338-8900
                                Office Fax:       (208) 345-8915

Clinical Research Experience:

“A Randomized, Multi-Center, Open-Label, Dose-Ranging Study Comparing the Safety and Efficacy of Xxxx 3.75 mg in Women with Endometriosis-Associated Pain.”

“A Multi-Center, Controlled, Randomized Trial Comparing the Safety and Efficacy of Xxxx to Xxxx in Women with Endometriosis-Associated Pain.”

“A Double-Blind, Randomized, Multicenter, Parallel Group Study Comparing the Therapeutic Equivalence and Safety of Xxxx Xxxx 4% Vaginal Cream (Perrigo) with Xxxx Vaginal Cream (McNeil Ortho) in the Treatment of Vulvovaginal Candidiasis.”

“A Randomized, Comparative, Multicenter, Safety and Contraceptive Efficacy Study of Two Xxxx Xxxx/Xxxx Estradiol Regimens, and One Xxxx Xxxx/Xxxx Estradiol Regimen (RWJ-10131) and Xxxx Fe 1/20.”

“A Phase II, Randomized, Double-Blind Parallel Group Study to Evaluate The Safety and Efficacy of Xxxx in Patients with Xxxx Xxxx.”

“A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Clinical Study to assess the effect of six months of repeated daily oral 500 and 1000 mg doses of Xxxx (INS-1) on the ovulatory endocrine and Metabolic abnormalities of women with PCOS.”

“A Randomized, Double-Blind, Dose-Ranging, Parallel-Group Study To Compare the Safety and Efficacy of Xxxx (CE10) (0.3, 0.625, and 1.25 mg modified release) with Placebo in Postmenopausal Women Suffering
From Moderate to Severe Vasomotor Symptoms.”

“A Dose-Range-Finding, Double-Blind, Randomized Placebo Controlled, Multicenter, Active-Comparator Study to Determine the Effect of Xxxx In Postmenopausal Women With Predominantly Urge Urinary
Incontinence.”

“Safety and Efficacy Comparison of Xxxx 0.75% Vaginal Cream and Xxxx In Patients With Bacterial Vaginosis: A Multicenter, Randomized, Single-Blinded, Parallel-Group Study.”

“A Mulitcenter, Randomized, Parallel-Group, Investigator-Blinded Study to Compare the Safety and Efficacy of Xxxx 1 Combination Pack in Bedtime versus Daytime Administration.”

“A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Fixed Dose, Multicenter Study to Evaluate the Efficacy, Safety and Toleration of Oral Xxxx Administered for 12 weeks to Pre-Menopausal
Women Who Have Been Diagnosed with Female Sexual Arousal Disorder.”

“A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose, Mulitcenter Study to Evaluate the Efficacy, Safety and Toleration of Oral Xxxx Administered for 12 weeks to Post-Menopausal Women Who have Been Diagnosed with Female Sexual Arousal Disorder.”

“A Phase III, Mulitcenter, Open-Label Study to Evaluate the Safety and Efficacy of Xxxx 90mcg and Xxxx 20mcg in a Continuous Daily Regimen For Oral Contraception.”

“A Phase II, Randomized, Double-Parallel Group Study to Evaluate the Safety and Efficacy of Xxxx in Patients with Uterine Leiomyomata.”

“Double-Blind Investigation of the Efficacy and Safety of Continuous Transdermal 1% 17 B-Xxxx in Combination with Xxxx Compared with Continuous Transdermal 1% 17 B-Xxxx Alone for Prevention of
Endometrial Hyperplasia in Post-Menopausal Women.

“A Double-Blind, Randomized, Placebo-Controlled Study of the safety And Efficacy of Xxxx and Xxxx Vaginal Inserts with Vaginal Atrophy.”

“A Randomized Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy and Safety of Daily Oral Administration of 10 mg of Xxxx Versus Placebo in Male and Female Subjects With Overactive Bladder.”

“An Open-Label, Long-Term Tolerability Study of Daily Oral Administration of 10 mg Xxxx in Male and Female Subjects with Overactive Bladder.”

“A Phase II, Randomized Study of Xxxx Versus Placebo and Xxxx in Post-menopausal Women with Osteopenia: Evaluation of the Dose Response Relationship of Xxxx on Markers of Skeletal and Lipid Metabolism and Bone Mineral Density.”

“A Mulitcenter, Randomized, Double-Blind, One Year Safety and Efficacy Study of Three Doses of an Xxxx capsule in the Prevention of Estrogen-induced Endometrial Hyperplasia in Post-Menopausal Women with Intact Uteri.”

“ A Prospective, Randomized, Double-Blind, Placebo-Controlled Evaluation of Topical Xxxx Administered at Home for the Treatment of Premenopausal Women With Female Sexual Arousal Disorder.”

“A Double-Blind, Placebo-Controlled Study of Urinary Frequency and Urgency Using Xxxx Xxxx 20 mg Tablets, Twice Daily, for 12 weeks Followed by a 6-Month, Open-label Treatment Phase in Patients with Overactive Bladder.”

“Xxxx versus Placebo in the Relief of Stress Incontinence.”

“A Multicenter, Double-Blind Comparison of Xxxx H.S. vs Estrogen Alone In the Treatment of Menopausal Women Complaining of Loss of Sexual Interest/
Desire.”

“A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center Study to Assess the Efficacy and Safety of Daily Oral Administration of 5 and 10 Mg Xxxxx in Patients Not Previously Exposed to Anticholinergic Drugs for the Treatment of Urgency Associated with Overactive Bladder”

“A Multi-center, Randomized, Parallel-group, Investigator-blinded Study to Compare the Safety, Therapeutic Efficacy, and Vulvovaginal Symptomatic Relief Of a single Vaginal Dose of Xxxx 500mg Suppository compared to a 7-Day Dose Of Miconazole Nitrate 2% vaginal cream in the Treatment of Vulvovaginal Candidiasis

“A multi-center, double-blind, double-dummy, randomized, placebo-controlled study comparing a 2.2 mg 17 beta-estradiol/0.69 mg levonorgestrel combination transdermal patch, and a 1 mg 17 beta-estradiol transdermal patch with a placebo patch in postmenopausal women to determine the lowest effective dose of estradiol for the relief of moderate to severe hot flushes”

“A Multi-center, Randomized, Parallel-group, Investigator-blinded Study to Compare the Safety, Therapeutic Efficacy, and Vulvovaginal Symptomatic Relief of a single Vaginal Dose of Xxxx 500 mg Suppository compared to a 7-Day Dose of Miconazole Nitrate 2% Vaginal Cream in the Treatment of Vulvovaginal Candidiasis.

“A Multi-center, Double-blind, Double-dummy, Randomized, Placebo-controlled Study Comparing a 2.2mg 17 beta-estradiol/0.69 mg levonorgestrel combination transdermal patch, and a 1 mg 17 beta-estradiol transdermal patch with a placebo patch in postmenopausal women to determine the lowest effective dose of estradiol for the relief of moderate to severe hot flashes.”

“ A Validation Study of the Sexual Interest Questionnaire (SIQ).”

“ A 12 month double-blind, randomized, parallel-group, placebo-controlled, multi-center trial to investigate the efficacy and safety of Xxxx Low Dose for the treatment of postmenopausal atrophic vaginitis symptoms.”

“A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Xxxx 2%/Xxxx 2% Vaginal Cream with Clindesse, Gynazole-1, and Placebo in the Treatment of Subjects with Mixed Bacterial Vaginosis/Vulvovaginal Candidiasis Infections.”

“Comparison of the Safety and Efficacy of a Unique Intravenous Iron Preparation (Xxxx) versus Oral Iron in the Treatment of Iron Deficiency Anemia Secondary to Heavy Uterine Bleeding.”

“A Double-Blind, Randomized, 6-month Evaluation of the Safety and Efficacy of Topical Xxxx in Hysterectiomized Women with Female Sexual Arousal Disorder.”

“A 12 Month, Open Label, Multicenter Study to Evaluate the Safety of a 1.3 g Oral Dose of a New Modified-Release Xxxx Formulation Administered Three Times Daily as Needed for up to 5 Days During The Menstrual Cycle in Women with Heavy Menstrual Bleeding Associated with Menorrhagia.”

Personal Notes

Married

3 children

Interests include: Hiking, Mountain Climbing, Family Vacations and Volunteering at the Free Medical Clinic.